Skip to content
OpenCapital
Get started

MaxCyte MXCT Q1 2026 earnings

Reported May 12, 2026 · Before market open

Revenue$9.7MBeat by $2.4MDiluted EPS-$0.04Beat by $0.06
Revenue estimate$7.3M
EPS estimate-$0.10

Next report

Aug 12, 2026 (in a month)
Revenue estimate$6.6M
EPS estimate-$0.12

Financials

Q1 2026

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$137.12M-74.1%
Enterprise value$140.05M-72.6%
P/S4.3×-9.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Segments

By product

See full
License$5.5M+18.2%
Assay And Other Service Revenue$482.0K+21.4%

By segment

See full
Cell Engineering Technology$9.7M-7.1%

Versus estimates

Revenue

Q1 2026$9.7MBeat by $2.4M
Q4 2025$7.3MMiss by $1.8MQ3 2025$6.8MMiss by $2.6MQ2 2025$8.5MMiss by $1.9MQ1 2025$10.4MBeat by $821.8KQ4 2024$8.7MMiss by $578.7K

Diluted EPS

Q1 2026-$0.04Beat by $0.06
Q4 2025-$0.06Beat by $0.02Q3 2025-$0.12Miss by $0.01Q2 2025-$0.12Miss by $0.02Q1 2025-$0.10In lineQ4 2024-$0.10Beat by $0.02

Ask the moment MaxCyte reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did MaxCyte report Q1 2026 earnings?
MaxCyte (MXCT) reported Q1 2026 earnings on May 12, 2026 before market open.
What were MaxCyte's Q1 2026 revenue and EPS?
MaxCyte reported revenue of $9.7M and diluted EPS of $-0.04 for Q1 2026.
Did MaxCyte beat estimates in Q1 2026?
Revenue beat the consensus estimate of $7.3M by $2.4M. EPS beat the consensus estimate of $-0.10 by $0.06.
How did MaxCyte's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 7.1% from $10.4M a year earlier and diluted EPS grew 60.0% from $-0.10.
Where can I find MaxCyte's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-059399) and the 10-Q periodic report (0001104659-26-060290) directly on SEC EDGAR. The filing index links above go to sec.gov.